Table 2.
Multivariate logistic regression analysis of the association of SSRIs with time course of PSF.
| All patients (n = 847) | Non-PSD patients (n = 598) | PSD patients (n = 249) | ||||
|---|---|---|---|---|---|---|
| OR (95% CI) | P value | OR (95% CI) | P value | OR (95% CI) | P value | |
| Non-PSF (n = 431) | reference | reference | reference | |||
| Incident PSF (n = 63) | 0.93 (0.49–1.76) | 0.815 | 1.33 (0.57–3.08) | 0.507 | 0.23 (0.05–0.96) | 0.044 |
| Recovered PSF (n = 209) | reference | reference | reference | |||
| Persistent PSF (n = 144) | 1.02 (0.60–1.74) | 0.944 | 0.97 (0.38–2.46) | 0.940 | 0.28 (0.09–0.90) | 0.033 |
The model was adjusted for age, sex, body mass index, hypertension, diabetes mellitus, hyperlipemia, smoking, drinking, TOAST classification, NIHSS, HAMA and Lubben score.
CI, confidence interval; HAMA, Hamilton Anxiety Scale; NIHSS, NIH Stroke Scale; OR, odds ration; PSD, poststroke depression; PSF, poststroke fatigue; TOAST, Trial of Org 10172 in Acute Stroke Treatment.